I hold BSc (Hons) and MSc in Zoology/Immunology from the University of Khartoum (Khartoum, Sudan) and PhD degree in Immunology/infection biology from Karolinska Institute (Stockholm, Sweden). I am currently a senior scientist, leading the human immunology research in the TB group.
My research focuses on identifying correlates of risk of TB in endemic areas and comprehensively characterising the host immune responses following TB vaccination and controlled human mycobacterial challenge. These studies also involve investigating human immune responses after delivery of TB vaccines via the aerosol route. I have established novel immune monitoring techniques for the evaluation of lung mucosal and systemic immune responses following both aerosol mycobacterial challenge and aerosol vaccination.
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Müller J. et al, (2019), JCI insight, 4
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
Current approaches toward identifying a correlate of immune protection from tuberculosis
Satti I. and McShane H., (2019), Expert Review of Vaccines, 18, 43 - 59
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
O’Shea MK. et al, (2018), Scientific Reports, 8